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OBJECTIVE: To assess feasibility, convergent validity and relia-
bility of the Italian version of the Infants’ Dermatitis Quality Of
Life Index (IDQOL) and the Family Dermatitis Index (FDI).
METHODS: Parents of 21 children with atopic dermatitis were
enrolled at the Policlinico Hospital in Modena and interviewed
on two separate occasions (6/7 days between the interviews).
Feasibility was tested by computing the number of missing
answers; convergent validity was tested by testing correlation
between the scores; reliability was tested in terms of internal con-
sistency and test-retest reproducibility. RESULTS: all the inter-
viewed persons answered to every question. The median severity
score was 1.00 (0–3), with no signiﬁcant differences between the
two interviews and good level of agreement (weighted kappa =
0.604). The IDQOL median score was 9.00 (from 7 to 17, in the
ﬁrst, to 16 in the second interview), with no signiﬁcant differ-
ences between the two interviews; Cronbach’s alpha >0.7; Intr-
aclass Correlation Coefﬁcient (ICC) between the ﬁrst and second
assessment =0.95; presence of biases excluded (Bland & Altman
method); the coefﬁcient of agreement for each IDQOL item
ranged from 0.632 (‘mealtimes’) to 1.000 (‘play’, “family activ-
ities”). The median DFI score was 5 (from 0 to 19, in the ﬁrst,
to 18, in the second interview), with no signiﬁcant differences
between the two interviews, Cronbach’s alpha >0.9, ICC
between the ﬁrst and second assessment =0.99, the presence of
biases excluded; coefﬁcients of agreement computed for each
item ranged from 0.638 (‘feeding’) to 0.908 (‘expenditure’). The
convergent validity between these instruments was satisfactory,
with high and statistically signiﬁcant correlation coefﬁcients.
CONCLUSIONS: The Italian version of IDQOL and DFI is fea-
sible, valid and reliable. These instruments can be used to eval-
uate QOL of young patients with atopic dermatitis and their
families and can be used to assist decisions on treatment and
health-care resource allocation.
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OBJECTIVES: Assess the impact of atopic dermatitis on the
patient’s sexuality. METHODS: Atopic patients consulting spon-
taneously their dermatologist were given two questionnaires: the
ﬁrst one was completed by the patient himself/herself and the
second, by the patient’s partner, if this was the case. Patients were
asked to ﬁll in a questionnaire on sexuality and two question-
naires on quality of life: a generic questionnaire (SF-12) and a
speciﬁc one for skin pathologies (DLQI). Partners were asked to
complete the same questionnaire on sexuality as well as the SF-
12 questionnaire. The dermatologist was asked to assess AD
severity using the SCORAD index. RESULTS: Sex ratio for our
population (n = 266) was 34.2% of men versus 65.8% of
women. Mean age of our population was 33.4 years old (SD:12).
The average number of years with atopic dermatitis was 18 years
(SD:13.8). Severity of AD was determined by the dermatologist
using the SCORAD index. According to this classiﬁcation, 1.6%
of our population presented a mild form of atopic dermatitis,
44.1% a moderate form and 54.3% a severe form. Only 10.5%
of interviewed subjects said that their atopic condition had never
affected their physical appearance. They were also 18.3% to
speak about their partner’s fear of catching the disease. For
57.5% of the subjects, atopic dermatitis resulted in, at least some
of the time, a decrease in sexual desire. Aspect of AD (redness,
dryness) was affecting their sexuality at least from time to time
for 55.4% of them. Regarding treatment, 46.8% declared an
impact of the latter on their sexuality. CONCLUSIONS: Results
of this study underline the sizable impact of atopic dermatitis 
on sexuality. Over one patient in two reported a decrease in
sexual desire. AD should hence be more considered as a public
health problem so as to provide patients with better global 
management.
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OBJECTIVE: Evaluation of Health-Related Quality-of-Life
(HRQoL) of atopic eczema (AE) in pediatric patients and their
families. METHODS: We conducted a naturalistic, multicenter
Cost-Of-Illness study. Data on AE patients with ﬂare-ups was
collected: socio-demographic, clinical, economic, HRQoL and
preferences towards pharmacological treatment. The following
results pertain to the children’s and their families’ HRQoL. Care-
givers’ HRQoL was evaluated with the EuroQol; disease-speciﬁc
questionnaires were used to evaluate families’ wellbeing (Der-
matitis Family Impact, DFI) and patients’ HRQoL: Infant’s Der-
matitis Quality Of Life Index (IDQOL) for patients aged 2–4
years, Children’s Dermatology Life Quality Index (CDLQI) for
patients aged 5–16 years (in every scales, 0 corresponds to good
and 30 to bad quality of life). Descriptive analyses and tests on
possible associations between children’s and families HRQoL
were conducted. RESULTS: A total of 83 children with their
caregivers (97.5% parents) were enrolled; 47% patients were
aged 2–4 years, 20.5% were 5–7 years old, 32.5% were 8–16
years old. At the enrollment the median IDQOL was 8 (0–21),
the median CDLQI was 4 (0–21). The median DFI was 8 (0–21).
No more than 5% of caregivers reported problems with the
EuroQol domains “mobility”, “self-care”, “usual activities”,
35.4% reported problems with “pain/discomfort”, 28.4% prob-
lems with “anxiety/depression”. DFI score was signiﬁcantly cor-
related with IDQOL and CDLQI (p < 0.0001) and all these
scores were moderately related to the caregivers’ perception of
“anxiety or depression” (p < 0.10). Patients and families’ well-
being was worse in the group of patients aged 2–4 years old (p
< 0.05), while it was similar among patients aged 5–16 years.
CONCLUSION: This study allowed us to evaluate the HRQoL
impairment attributable to AE and the repercussions on families’
wellbeing. Good levels of validity and reliability of the Italian
version of the disease-speciﬁc questionnaires used in this study
was conﬁrmed.
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OBJECTIVE: To assess feasibility, content validity and reliabil-
ity of the Italian version of the Dermatology Life Quality Index
(DLQI). METHODS: Twenty-two patients (median age 35 years,
from 18 to 64, 22.7% males) affected by skin diseases, were
recruited at the Policlinico Hospital in Modena and asked to
complete the DLQI on two separate occasions (six or seven days
between the two interviews). The median DLQI score was 8.00
(1–21) and 8.50 (2–23) on the ﬁrst and second interview, respec-
